PT - JOURNAL ARTICLE AU - Barbero, Angela María AU - Moriconi, Nicolás Diego AU - Palma, Sabina AU - Celano, Josefina AU - Balbi, María Gracia AU - Morro, Lorenzo Sebastián AU - Calvo Zarlenga, María Martina AU - Suárez, Jorgelina AU - Martínez, María Guadalupe AU - Machain, Mónica Graciela AU - Altamiranda, Carlos Gabriel AU - Erbiti, Gabriel AU - Hernández Del Pino, Rodrigo Emanuel AU - Pasquinelli, Virginia TI - Unveiling the threat: Characterization of <em>Clostridioides difficile</em> Infection in the Northwest Region of Buenos Aires between 2019-2023 and Associated Risk Factors redefined through a Meta-Analysis AID - 10.1101/2024.04.25.24306385 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.25.24306385 4099 - http://medrxiv.org/content/early/2024/07/29/2024.04.25.24306385.short 4100 - http://medrxiv.org/content/early/2024/07/29/2024.04.25.24306385.full AB - Clostridioides difficile stands as the leading cause of hospital acquired enteric infection in developed countries. In Argentina, the epidemiology of Clostridioides difficile infection (CDI) is currently poorly characterized. Therefore, we conducted a retrospective case-control study evaluating the prevalence of CDI in 249 stool samples collected between 2019 and 2023 in the Northwest region of Buenos Aires. The presence of C. difficile was detected by combining three techniques (EIA, PCR and toxigenic culture) in a diagnostic algorithm. Clinical and demographic data from patients was also analyzed to identify CDI-associated risk factors. 1 in 5 patients presented C. difficile as the etiological agent of diarrhea and the 80% of CDI+ cases carried toxigenic strains, with a third of cases acquired in the community. Age ≥69 years, previous use of antibiotics, previous hospitalization and previous episodes of CDI emerged as predisposing factors for CDI in our study cohort. Blood parameters such as an elevated number of leukocytes and platelets, a decreased basophil count, and an increased urea concentration were identified as indicators of CDI. We also carried out a systematic review and a meta-analysis where we contrasted our results with 39 studies selected from different countries around the world. At the global level, the meta-analysis highlighted advanced age, previous consumption of antibiotics and previous hospitalization as CDI risk factors and the leukocyte count as an indicator of CDI. These results emphasize the importance of epidemiological studies and reveal crucial information for healthcare decision-making regarding CDI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Universidad Nacional del Noroeste de la Provincia de Buenos Aires [grant numbers SIB 0618/2019, SIB 2113/2022 and Proyectos de Investigación Interdisciplinarios de la UNNOBA Res. CS 2190/2022, to VP]. Agencia Nacional de Promoción Cientifica y Tecnológica, Fondo para la Investigación Cientifica y Tecnológica [ANPCyT-FONCyT, grant numbers PICT A 2017-1896 and PICT-2021-I-A-01119 to VP; PICT 2018-03084 IB to RHDP, PICT-2021-I-INVI-00584 to AB and PICT-2021-I-INVI-00208 to SP]. UNNOBA FONCyT [grant number PICTO 2019-00007 to RHDP and VP]. Consejo Nacional de Investigaciones Cientıificas y Técnicas [CONICET, grant number PIP 2021 11220200103137CO to VP and RHDP].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UNNOBA (Universidad Nacional del Noroeste de la Provincia de Buenos Aires) Ethics Committee (COENOBA) gave ethical approval for this work (file No. 2919-1594/17).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.